Rare Disease Day 2023

Alentis ‘Shares Their Colors’ for ANCA-Associated Glomerulonephritis and Idiopathic Pulmonary Fibrosis Basel, Switzerland – 28 February 2023Rare Disease Day takes place annually on the last day of February to raise awareness for the more than 7,000 rare diseases and their impact on patients’ lives. Physicians, patients, patient advocates, researchers and medical & biotech companies from around the world shine a light on these little-known diseases and champion the need for education, research funding and access to treatment.Alentis has chosen to spread the word through a team event showing support for patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis and Idiopathic…

Continue ReadingRare Disease Day 2023

ALENTIS THERAPEUTICS makes key leadership appointments

Alentis names Markus Meyer COO and promotes Alberto Toso to SVP Head Oncology and Geoffrey Teixeira to SVP Head Fibrosis Basel, Switzerland – 17 February 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Markus Meyer to Chief Operations Officer (COO), Geoffrey Teixeira to SVP Head Fibrosis, Alberto Toso to SVP Head Oncology, effective 15 February.In his new role, Markus will be responsible for leading the development of Alentis’ portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’ pipeline includes…

Continue ReadingALENTIS THERAPEUTICS makes key leadership appointments

Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) F02 found to be well tolerated at all doses with a good safety profile and demonstrated initial evidence of on-target biological activity Planned initiation of first-in-human clinical study for lead oncology asset ALE.C04 in H2 2023 Basel, Switzerland – 9 January 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announces positive results from a single ascending dose Phase 1 study of its lead program, ALE.F02, currently in development for the treatment of advanced kidney,…

Continue ReadingPositive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer

Basel, Switzerland – 5 January 2023 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Dr. Luigi Manenti as Chief Medical Officer (CMO).In his new role, Dr. Manenti will be responsible for leading the development of Alentis’s portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’s pipeline includes ALE.F02, which is currently in Phase 1 clinical studies for the treatment of advanced kidney, liver and lung fibrosis; and ALE.C04, currently at IND submission stage to treat CLDN1+ solid…

Continue ReadingAlentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer

Preclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs

Important data provide further validation of Alentis’ approach to develop first-in-class anti-Claudin-1 monoclonal antibodies to treat advanced fibrosis and fibrotic cancersBasel, Switzerland – 21 December 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announces that Scientific Founder Professor Thomas Baumert’s team has published an article in the peer-reviewed journal Science Translational Medicine providing preclinical proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs.Severe tissue fibrosis is a key driver of end-stage organ failure and cancer, overall accounting for up to 45%…

Continue ReadingPreclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs

Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target Claudin-1 to make solid tumors vulnerable to treatmentBasel, Switzerland, December 1, 2022 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Head of Oncology, will present a poster at the ESMO Immuno-Oncology Congress in Geneva, Switzerland (and virtually), from 7-9 December 2022. The poster, CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform, presents evidence that non-junctional Claudin-1 is overexpressed in different solid tumors, drives T-cell exclusion and resistance to checkpoint inhibitors (CPI). Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04…

Continue ReadingAlentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022

Basel, Switzerland, November 4, 2022 – Alentis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough treatments for fibrotic diseases and cancer, today announced that there will be two presentations about the treatment of biliary disease and cancer using Claudin-1 monoclonal antibodies at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022, taking place from November 4th to 8th in Washington DC, USA. Presentation: TREATMENT OF CHOLANGIOCARCINOMA WITH A HUMANIZED ANTI-CLAUDIN-1 MONOCLONAL ANTIBODY Presenter: Marion Muller, MS, Inserm, U1110 and University of Strasbourg, France Session: Parallel 22: Experimental and Translational Hepatobiliary…

Continue ReadingAlentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022

Article published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma

Breakthrough results provide robust pre-clinical proof-of-concept for Claudin-1 monoclonal antibodies as potential first in-class compounds for HCCPotential shown to break the plateau of limited treatment response in advanced HCCThese results pave the way for the clinical development of Claudin-1 specific antibodies for treatment of patients with HCCBasel, Switzerland – 2 November 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announces that Scientific Founder Professor Thomas Baumert’s team has published an article on the role of Claudin-1 (CLDN1) in the treatment of hepatocellular carcinoma (HCC) The Journal of…

Continue ReadingArticle published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma

Swiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis

Alentis will collaborate with the FHNW School of Life Sciences to identify translational biomarkers of Claudin-1 for use in future Alentis trialsBasel, Switzerland – 27 September 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announced the Swiss Innovation Agency, Innosuisse, will co-fund a research collaboration with the FHNW School of Life Sciences to accelerate the discovery of Claudin-1-associated biomarkers for fibrosis.Claudin-1 (CLDN1) is a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of organ fibrosis and fibrotic…

Continue ReadingSwiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis

Alentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment ofLiver and Kidney Fibrosis FDA greenlights Alentis Phase 1 protocol study designAlentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 -- Alentis Therapeutics, AG today announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1, currently being developed for the treatment of advanced unmet liver and kidney fibrosis. Alentis is a clinical stage biopharma focused on discovering and developing novel therapies for the treatment of unmet fibrotic diseases. "ALE.F02 has…

Continue ReadingAlentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

End of content

No more pages to load